




MONASH
University

MYELOMA AND RELATED DISEASES REGISTRY (MRDR)

2022 ANNUAL REPORT



The MRDR is a clinical quality registry established in 2012 that aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.

The registry has participating hospitals and clinics in all jurisdictions in Australia and New Zealand. Data collected includes patient demographics, clinical characteristics, test results at diagnosis, treatment, response, follow-up and outcomes including survival and quality of life.


BENCHMARKING TO IMPROVE CARE

The MRDR provides six-monthly data reports to participating sites comparing each site's registry data to the rest of the MRDR cohort. Treatment varies between centres, and these reports allow treating institutes and clinicians to identify areas of difference and where there may be opportunities for improvement. In this way the MRDR facilitates work towards higher quality care.

MRDR NETWORK


The established MRDR network and data collection infrastructure of >50 participating metropolitan & regional, public & private health services throughout Australia and New Zealand provides a solid base from which to conduct many and diverse projects, and enhances our capacity for rapid translation of results. In addition, the MRDR's close association with relevant professional and research groups, Myeloma Australia (a national patient advocacy group), policy-makers and industry partners, further strengthens our capacity for research translation.

The MRDR informs national and international policy, guidelines and practice through representation of Management and Steering Committee members in:



- Haematology Society of ANZ (HSANZ)
- Haematology Society of ANZ Nursing Group (HSANZ NG)
- Myeloma Special Practice Network (M-SPN) of the HSANZ NG
- Cancer Nurses Society of Australia (CNSA)
- Myeloma Australia
- Myeloma Australia Medical Scientific Advisory Group (MSAG)
- International Myeloma Working Group (IMWG)
- Australasian Myeloma Research Consortium (AMaRC)
- Synergistic relationship with pharmaceutical industry partners


MRDR 2022 AT A GLANCE



5836 PATIENTS REGISTERED


803 NEW PATIENTS

- 73% MULTIPLE MYELOMA (MM)
- 25% MGUS / SMOULDERING MM¹
- 2% PCL² / PLASMACYTOMA




MYELOMA 1000 BIOBANK: THE ONLY PROSPECTIVE FULLY ANNOTATED 'LIQUID BIOPSY' BIOBANK IN THE WORLD

607 MYELOMA 1000 BIOBANK PATIENTS:




15 MYELOMA 1000 APPROVED SITES



49 REQUESTS: DATA/ANALYSES/REPORTS



- 21 INVESTIGATOR-DRIVEN
- 15 OPERATIONAL / ONGOING REPORTS
- 12 INDUSTRY
- 1 GOVERNMENT



MULTIPLE MYELOMA

PATIENTS

AGE (MEDIAN): 68 YEARS
FEMALE 40% / MALE 60%

SURVIVAL

57% OF PATIENTS SURVIVE
TO 5 YEARS

STEM CELL TRANSPLANTS IN PATIENTS <70 YEARS⁴

ALL PATIENTS: 74%
<65 YEARS AT DIAGNOSIS: 80%
65-70 YEARS AT DIAGNOSIS: 60%

1. Possible precursor disease for MM
2. PCL = Plasma cell leukemia
3. Ethics approval and local governance authorisation obtained
4. Patients at least 1 year post-diagnosis with some post-registration follow-up.

MRDR RESEARCH HIGHLIGHTS FOR 2022

EpiMAP Myeloma: Epidemiological modelling to deliver better care for Australian patients with myeloma

Project Funding:

Medical Research Future Fund (MRFF) – Targeted Health System and Community Organisation Research

Chief investigators:

Zoe McQuilten, Dennis Petrie, Andrew Spencer, Erica Wood, Anthony Harris, Laura Fanning

The project is developing and validating a novel patient-level simulation model to estimate the numbers of patients in Australia with MM who will require treatment over the next five years, their disease trajectories, outcomes, and associated quality of life and healthcare costs. The model uses real world data from the MRDR, which will be linked to Commonwealth administrative data and validated with international evidence. The model will be available to inform health-care policy and service delivery planning, including decision-making for future funding of high-cost MM therapies.

The model is ready for validation and can calibrate results of pivotal clinical trials using MRDR data and simulate how a new therapy would be expected to change outcomes in real-world Australian clinical practice. Communication with the government on its use is in progress.



IMPROVE: Immunoglobulins in myeloma patients: research into outcomes, variation in practice and epidemiology

Project Funding:

National Blood Authority Research and Development pilot project (IgP04)

Chief investigators:

Erica Wood, Krystal Bergin, Philip Crispin, Claire Dendle, Zoe McQuilten, Elizabeth Moore, Orla Morrissey, Arul Earnest, Andrew Spencer, Robert Weinkove.

Immunoglobulin (Ig) therapy is made from donated plasma. MM is one of the most common indications for its use in Australia, with increasing demand and much variation in practice. It is also costly (over \$60M spent annually in MM in Australia). The IMPROVE study has collected real world data in Australia and New Zealand on immunoglobulin use in MM in response to infection. Recruitment and follow-up are complete, and a final report was submitted to the National Blood Authority shedding light on current practice, costs and outcomes in Ig use. This report and recommendations will guide policy and clinical practice to improve the stewardship of this resource in Australia.

Further work is in progress, with the opportunity for collaboration with young investigators, to provide valuable data to government on blood product use.



MY-PROMPT-2: More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures

Project Funding:

MRFF – Rare Cancers, Rare Diseases and Unmet Needs

Chief investigators:

Andrew Spencer, Claudia Rutherford, John Reynolds, P Joy Ho, Zoe McQuilten, Elizabeth Moore, Tracy King, Erica Wood, Simon Harrison, Adam Irving.

The MY-PROMPT-2 trial will test whether real-time symptom feedback to clinicians improves duration on therapy in patients with relapsed MM receiving standard care. MM treatment is complex and costly, however survival benefits seen in clinical trials are often not reflected in clinical practice, partly because many patients stop therapy early due to side-effects, reducing the survival benefit of optimal therapy duration. If clinicians are aware of emerging symptoms, leading to timely intervention, duration on therapy could be optimised, resulting in more efficient use of these high-cost therapies, and better patient outcomes. The trial is open for recruitment at approved, activated sites.



The MRDR encourages and supports all researchers in developing and pursuing their question of interest.

FRAIL-M: Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma

Project Funding:

MRFF – Low Survival Cancers and Diseases

Chief investigators:

Andrew Spencer, Zoe McQuilten, Hang Quach, Peter Mollee, Erica Wood, John Reynolds, Ruth Hubbard, Richard De Abreu Lourenco.

The FRAIL-M trial will identify which competing treatment options are more appropriate in transplant-ineligible myeloma patients according to frailty status. Adapting certain standard treatment regimens according to frailty assessment in this patient group is recommended in Australian guidelines, however it had not been tested in a clinical trial, nor had the two most common treatment options been compared. Findings from this study will address these gaps, and provide a robust framework for optimisation of treatment in transplant-ineligible myeloma patients. The trial will inform more cost-effective use of publicly funded high-cost front-line anti-MM therapies such as bortezomib and lenalidomide. FRAIL-M is recruiting in both Australia and New Zealand



MRDR COLLABORATIONS

Asia-Pacific (APAC) MRDR



The APAC MRDR is a sister registry to the MRDR in the Asia-Pacific region, and collects the same data to facilitate comparisons between countries. APAC MRDR currently has 22 hospitals enrolling participants in Korea, Malaysia, Singapore and Taiwan, with China soon to join. With over 1300 patients currently on the registry there is great interest in this region, and with the data maturing, collaborations with the ANZ MRDR in several analyses have commenced, and are anticipated with other research groups.

apacmrdr.org

AMaRC: The Australasian Myeloma Research Consortium



AMaRC is a not-for-profit myeloma clinical trial research group composed of clinicians and scientists who develop and conduct investigator-led early phase and proof-of-concept studies, trialing novel drug and biologic products in Australia and New Zealand. AMaRC have valued partnerships with the pharmaceutical industry, the Myeloma Research Group laboratory, the Australasian Leukaemia & Lymphoma Group (ALLG), and Myeloma Australia. In some studies, AMaRC leverages the MRDR's established infrastructure and national site network as a platform for MM trials.

amarconline.org

Myeloma Australia



Myeloma Australia (MA) is the only myeloma-specific patient advocacy group in Australia. They support, educate, inform, and empower people who are living with MM, and their loved ones. The MRDR and MA work closely together, including through representation on the MRDR Steering Committee, support of and strong MRDR presence at the National Myeloma Workshop hosted by MA, funding support, and collaboration on grant applications and a range of research projects. The MRDR provides quarterly data reports to MA's Medical and Scientific Advisory Group - the peak body convened to collaborate and facilitate advances and medical care for MM in Australia.

myeloma.org.au

ANZ & APAC MRDR: COMBINED DATA SNAPSHOT

Analyses using combined ANZ and APAC MRDR data have been completed for several data requests (Presentations page 10) showing regional variation and the potential for this collaboration.

In table 2 and 3 we provide a snapshot of the combined MRDR data by location from 1 January 2018 to 3 January 2023.

Table 1. Current site accrual

	TOTAL	AUSTRALIA	NEW ZEALAND	KOREA	SINGAPORE	MALAYSIA	TAIWAN
ACTIVE HOSPITALS	73	43	8	11	3	6	2

Table 2. Age in years at diagnosis and gender for patients with multiple myeloma (MM)

	TOTAL	AUSTRALIA	NEW ZEALAND	KOREA	SINGAPORE	MALAYSIA	TAIWAN
N	3793	2112	720	753	131	73	16
AGE, MEDIAN (IQR)^	67 (59, 74)	68 (59, 75)	69 (61, 76)	65 (58, 72)	67 (60, 73)	64 (59, 70)	72 (64, 77)
AGE >70 YEARS^	39%	41%	45%	29%	40%	26%	63%
GENDER (MALE)	60%	62%	60%	57%	53%	59%	56%

Table 3. Most common MM chemotherapy regimens and patients who received an ASCT

	AUSTRALIA	NEW ZEALAND	KOREA	SINGAPORE	MALAYSIA	TAIWAN
MOST COMMON 1L	VCd (34%)	VCd (70%)	VTd (50%)	VRd (23%)	VCd (45%)	N/A
MOST COMMON 1L, NO ASCT	VCd (30%)	VCd (66%)	MPV (42%)	VCd (25%)	VCd (63%)	N/A
MOST COMMON 2L	DVd (19%)	VTd (26%)	KRd (39%)	DRd (16%)	VRd (30%)	N/A
RECEIVED ASCT*	54%	40%	55%	42%	39%	N/A
- AGE <70 YEARS**^	81%	69%	77%	64%	48%	N/A
- AGE >70 YEARS**^	12%	4.2%	0.8%	5.3%	0%	N/A

1L: first-line therapy, 2L: second-line therapy, ASCT: Autologous stem cell transplant.

* Only patients with at least 1-year post-diagnosis and with some follow-up data post-registration were included.

^Age: at Diagnosis; for Singapore, Date of Birth unknown – age estimated using 01 July “Year of Birth”. N/A: not available/insufficient data.

Chemotherapy Codes

CODE	CHEMOTHERAPY REGIMEN
DRd	daratumumab, lenalidomide, dexamethasone
DVd	daratumumab, bortezomib, dexamethasone
KRd	carfilzomib, lenalidomide, dexamethasone
MPV	melphalan, prednisolone, bortezomib
VCd	bortezomib, cyclophosphamide, dexamethasone
VRd	bortezomib, lenalidomide, dexamethasone
VTd	bortezomib, thalidomide, dexamethasone

MRDR PEER-REVIEWED PUBLICATIONS TO DATE

The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population

Joanne Tan, Cameron Wellard, Elizabeth Moore, Peter Mollee, Rajeev Rajagopal, Hang Quach, Simon Harrison, Emma-Jane McDonald, P Joy Ho, Miles Prince, Bradley Augustson, Philip Campbell, Zoe McQuilten, Erica Wood, Andrew Spencer; Myeloma and Related Diseases Registry Investigators. Br J Haematol. 2023 Jan;200(2):e17-e21. <https://doi.org/10.1111/bjh.18536>.

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Zoe McQuilten, Cameron Wellard, Elizabeth Moore, Bradley Augustson, Krystal Bergin, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Brian Rosengarten, Patricia Walker, Erica Wood, Andrew Spencer; Australian and New Zealand Myeloma and Related Diseases Registry. Br J Haematol. 2022 Sep;198(5):830-837. doi: 10.1111/bjh.18324.

Māori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Elizabeth Moore, Hilary Blacklock, Cameron Wellard, Ruth Spearing, Luke Merriman, Sarah Poplar, Anup George, Bart Baker, Henry Chan, Zoe McQuilten, Erica Wood, Andrew Spencer on behalf of the MRDR investigators. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8): e762-e769. doi: 10.1016/j.clml.2022.04.004.

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.

Stephen Boyle, Cameron Wellard, Elizabeth Moore, Hilary Blacklock, Simon Harrison, P Joy Ho, Jay Hocking, Zoe McQuilten, Hang Quach, Ruth Spearing, Erica Wood, Andrew Spencer, Peter Mollee, Myeloma and Related Diseases Registry investigators. Eur J Haematol. 2021 Oct;107(4):497-499. doi: 10.1111/ejh.13677u

Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).

Krystal Bergin, Cameron Wellard, Bradley Augustson, Rachel Cooke, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Elizabeth Moore, Zoe McQuilten, Erica Wood, Andrew Spencer, Australian and New Zealand Myeloma and Related Diseases Registry investigators. Bone Marrow Transplant. 2021 Oct;56(10):2533-2543. doi: 10.1038/s41409-021-01308-8

The myeloma landscape in Australia and New Zealand: the first eight years of the Myeloma and Related Diseases Registry (MRDR).

Krystal Bergin, Cameron Wellard, Elizabeth Moore, Zoe McQuilten, Bradley Augustson, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Erica Wood, Andrew Spencer, Australian and New Zealand Myeloma and Related Diseases Registry investigators. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e510-e520. doi: 10.1016/j.clml.2021.01.01

Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial.

Elizabeth Moore, Tracy King, Erica Wood, Rasa Ruseckaite, Daniela Klarica, Andrew Spencer, P Joy Ho, Hang Quach, Miles Prince, Zoe McQuilten. Am J Hematol. 2020 Jul;95(7):E178-E181. doi: 10.1002/ajh.25815.

Renal impairment at diagnosis in myeloma: patient characteristics, treatment, and impact on outcomes. Results from the Australia and New Zealand Myeloma and Related Diseases Registry.

P Joy Ho, Elizabeth Moore, Zoe McQuilten, Cameron Wellard, Krystal Bergin, Bradley Augustson, Hilary Blacklock, Simon Harrison, Noemi Horvath, Tracy King, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Erica Wood, Andrew Spencer. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424. doi: 10.1016/j.clml.2019.05.010.

Myeloma in the Real World: what is really happening?

Krystal Bergin, Zoe McQuilten, Elizabeth Moore, Erica Wood, Andrew Spencer. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):133-144.e1. doi: 10.1016/j.clml.2016.12.002.

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry.

Krystal Bergin, Elizabeth Moore, Zoe McQuilten, Erica Wood, Bradley Augustson, Hilary Blacklock, P Joy Ho, Noemi Horvath, Tracy King, John McNeil, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Andrew Spencer. BMC Med Res Methodol. 2016 Nov 9;16(1):151. doi: 10.1186/s12874-016-0250-z.

MRDR PRESENTATIONS 2022

Australian Society for Medical Research, National Scientific Conference November 2022, Sydney

CTX-1 as a blood-based biomarker to identify risk of progression from smouldering myeloma to multiple myeloma (Oral)

Melissa Cantley, Angelina Yong, Duncan Hewett, Oi Lin Lee, Cindy Lee, Jo Gardiner, Rachael Sampson, Bao-Cuong Pham, Cameron Wellard, Tiffany Khong, Elizabeth Moore, Andrew Spencer, Noemi Horvath, L. Bik To, Andrew Zannettino, Kate Vandyke.

National Myeloma Workshop October 2022, Yarra Valley

MRDR and AMaRC trials update (Oral)

Sueh-Li Lim, Khoa Le, Andrew Spencer.

Australian data from the Myeloma and Related Disease Registry (Oral)

Krystal Bergin, Cameron Wellard, Elizabeth Moore, Zoe McQuilten, Bradley Augustson, Hilary Blacklock, Simon Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Erica Wood, Andrew Spencer.

Validation of the second revision of the International Staging System in a real-world myeloma population (R2-ISS): A Myeloma and Related Diseases Registry (MRDR) Study (Poster)

Joanne Tan, Cameron Wellard, Elizabeth Moore, Peter Mollee, Rajeev Rajagopal, Hang Quach, Simon Harrison, Emma-Jane McDonald, P Joy Ho, Miles Prince, Bradley Augustson, Philip Campbell, Zoe McQuilten, Erica Wood, Andrew Spencer.

Real-world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and the Asia-Pacific Myeloma and Related Diseases Registries (Poster)

Justin Ng, Elizabeth Moore, Pin-Yen Chen, Cameron Wellard, Peter Mollee, Rajeev Rajagopal, Hang Quach, Jian Hou, Jin Lu, Je-Jung Lee, Kihyun Kim, Wee Joo Chng, Andrew Spencer.

Blood September 2022, Sydney

MRDR Annual Investigator and Interest Group breakfast meeting (hybrid)

Myeloma in ANZ: MRDR progress and results

Andrew Spencer et al.

More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: introduction to the MY-PROMPT-2 trial.

Tina van Tonder et al.

Real-world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the ANZ, and the APAC MRDR).

Justin Ng et al.

Asia-Pacific MRDR: progress and results

Andrew Spencer et al.

Presentations

CTX-1 levels can predict individuals at high risk of progression from smouldering myeloma to multiple myeloma (Oral)

Melissa Cantley, Angelina Yong, Duncan Hewett, Oi Lin Lee, Cindy Lee, Jo Gardiner, Rachael Sampson, Bao-Cuong Pham, Cameron Wellard, Tiffany Khong, Elizabeth Moore, Andrew Spencer, Noemi Horvath, L. Bik To, Andrew Zannettino, Kate Vandyke

Continuing poor outlook for relapsed Australian Multiple Myeloma (MM) patients: Impact of limited available therapies (Oral)

Sueh-li Lim, Cameron Wellard, Andrew Spencer.

Infection patterns and outcomes in patients with newly diagnosed multiple myeloma: Preliminary results from the IMPROVE (Immunoglobulins in myeloma patients: research into outcomes, variation in practice and epidemiology) Cohort Study (Poster)

Khai Li Chai, Laura Sellick, Krystal Bergin, Hilary Blacklock, Rachel Cooke, Philip Crispin, Claire Dendle, Arul Earnest, Jane Estell, Cecily Forsyth, Nada Hamad, Simon Harrison, Ian Kerridge, Peter Mollee, Elizabeth Moore, Orla Morrissey, Nick Murphy, Anita Shetty, Andrew Spencer, Neil Waters, Robert Weinkove, Cameron Wellard, Zoe McQuilten, Erica Wood.

Variation in use of immunoglobulin and impact on survival in multiple myeloma: A report from the Australia/New Zealand MRDR and Asia-Pacific MRDR (Poster)

Khai Li Chai, Cameron Wellard, Naomi Aoki, Elizabeth Moore, Thao Le, Bradley Augustson, Akshay Bapat, Hilary Anne Blacklock, Wee Joo Chng, Rachel Cooke, Cecily Forsyth, Yeow Tee Goh, Nada Hamad, Simon Harrison, P Joy Ho, Jay Hocking, Ian Kerridge, Jin Seok Kim, Kihyun Kim, Tracy King, Georgia McCaughan, Peter Mollee, Orla Morrissey, Nicholas Murphy, Hang Quach, Xuan Ni Tan, Allison Tso, Kimberly Wong, Sung-Soo Yoon, Andrew Spencer, Erica Wood, Zoe McQuilten.

Epidemiological Modelling of Australian Patients with Myeloma, EpiMAP Myeloma (Poster)

Adam Irving, Dennis Petrie, Laura Fanning, Anthony Harris, Andrew Spencer, Erica Wood, Cameron Wellard, Kim Huynh, Elizabeth Moore, Neil Waters, Zoe McQuilten.

Validation of the second revision of the International Staging System in a real-world myeloma population (R2-ISS): A Myeloma and Related Diseases Registry (MRDR) Study (Poster)

Joanne Tan, Cameron Wellard, Elizabeth Moore, Peter Mollee, Rajeev Rajagopal, Hang Quach, Simon Harrison, Emma-Jane McDonald, P Joy Ho, Miles Prince, Bradley Augustson, Philip Campbell, Zoe McQuilten, Erica Wood, Andrew Spence.

Real-world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and the Asia-Pacific Myeloma and Related Diseases Registries (Poster)

Justin Ng, Elizabeth Moore, Pin-Yen Chen, Cameron Wellard, Peter Mollee, Rajeev Rajagopal, Hang Quach, Jian Hou, Jin Lu, Je-Jung Lee, Kihyun Kim, Wee Joo Chng, Andrew Spencer.

International Myeloma Society Meeting August 2022, Los Angeles

Real world experience of induction therapy for treatment of newly diagnosed multiple myeloma: an analysis from the Australian and New Zealand, and Asia-Pacific Myeloma and related diseases registries (Poster)

Justin Ng, Elizabeth Moore, Pin-Yen Chen, Cameron Wellard, Peter Mollee, Rajeev Rajagopal, Hang Quach, Jian Hou, Jin Lu, Je-Jung Lee, Kihyun Kim, Wee Joo Chng, Andrew Spencer

Validation of the second revision of the international staging system in a real-world myeloma population: a myeloma and related diseases registry study (Poster)

Joanne Tan, Cameron Wellard, Elizabeth Moore, Peter Mollee, Rajeev Rajagopal, Hang Quach, Simon Harrison, Emma-Jane McDonald, P Joy Ho, Miles Prince, Bradley Augustson, Philip Campbell, Zoe McQuilten, Erica Wood, Andrew Spencer Erica Wood, Zoe McQuilten, Andrew Spencer.

EHA Congress June 2022, Vienna (hybrid)

Variation in use of immunoglobulin and impact on survival in multiple myeloma: A report from the Australia/New Zealand MRDR and Asia-Pacific MRDR (e-Poster)

Khai Li Chai, Cameron Wellard, Naomi Aoki, Elizabeth Moore, Thao Le, Bradley Augustson, Akshay Bapat, Hilary Anne Blacklock, Wee Joo Chng, Rachel Cooke, Cecily Forsyth, Yeow Tee Goh, Nada Hamad, Simon Harrison, P Joy Ho, Jay Hocking, Ian Kerridge, Jin Seok Kim, Kihyun Kim, Tracy King, Georgia McCaughan, Peter Mollee, Orla Morrissey, Nicholas Murphy, Hang Quach, Xuan Ni Tan, Allison Tso, Kimberly Wong, Sung-Soo Yoon, Andrew Spencer, Erica Wood, Zoe McQuilten.

The European Society for Blood and Marrow Transplantation (EBMT) Meeting March 2022, (Virtual)

Long-term follow-up of tandem autologous plus non-myeloablative allogeneic transplant in relapsed myeloma: An Australian report from the Alfred and the Myeloma and Related Diseases Registry (MRDR) (Poster)

Aditya Tedjaseputra, Tongted Das, Cameron Wellard, Andrew Spencer.

MRDR SITES AND PRINCIPAL INVESTIGATORS

Adelaide Cancer Centre: Stanley Cheung
Alfred Hospital: Andrew Spencer
Auckland Hospital: Nicole Chien
Austin Hospital: Jay Hocking
Bairnsdale Regional Health Service: Amanda Ormerod
Ballarat Hospital: Swe Htet
Border Medical and Oncology: Anish Puliyyail
Box Hill Hospital: Yee-Shuen Chong
Cabrinia Hospital: Gaurav Srivastava
Calvary Mater Newcastle: Wojt Janowski
Canberra Hospital: Edwin Lee (Acting)
Central Coast Haematology: Cecily Forsyth
Central Gippsland Health Service: Amanda Ormerod
Christchurch Hospital: Emma-Jane McDonald
Concord Hospital: Jane Estell
Dunedin Hospital: Ian Morison
Epworth Freemasons Hospital: Miles Prince
Fiona Stanley Hospital: Stephanie Lam
Flinders Medical Centre: Craig Wallington-Gates
Frankston Hospital: Patricia Walker
Geelong Hospital: Philip Campbell
Griffith Hospital: Nada Hamad
Hollywood Private Hospital: Bradley Augustson
ICON Cancer Care: Ian Irving
Latrobe Regional Hospital: Tricia Wright
Launceston General Hospital: Jessica Heenan
Lismore Hospital: Louise Imlay
Liverpool Hospital: Sylvia Ling
Lyell McEwin Hospital: Stanley Cheung
Middlemore Hospital: Rajeev Rajagopal
Monash Medical Centre: Michael Low
Nelson Hospital: Luke Merriman
Nepean Cancer Centre: Anita Shetty
Northern Hospital: Rachel Cooke
North Shore Hospital: Anna Elinder-Camburn
Orange Health Service: Charmaine Wong
Palmerston North Hospital: Bart Baker
Peter Mac / Royal Melbourne: Simon Harrison
Princess Alexandra Hospital: Peter Mollee
Royal Adelaide Hospital: Noemi Horvath

Royal Brisbane & Women's Hospital: Nicholas Weber
Royal Darwin Hospital: Tina Noutsos
Royal Hobart Hospital: Nick Murphy
Royal North Shore Hospital: Ian Kerridge
Royal Prince Alfred Hospital: P Joy Ho
Sir Charles Gairdner Hospital: Bradley Augustson
St George Hospital: Sundra Ramanathan
St Vincent's Hospital, Melbourne: Hang Quach
St Vincent's Hospital, Sydney: Nada Hamad
Sunshine Hospital: William Renwick
Sunshine Coast University Hospital: Anthony Powell
Tamworth Hospital: Israfil Baluwala
Toowoomba Hospital: Howard Mutsando
Townsville Hospital: Andrew Birchley
Wagga Wagga Hospital: Nada Hamad
Wellington Hospital: Anup George
Whangarei Hospital: Sarah Poplar

MRDR STUDENTS

Sueh-li Lim:

Monash University, current PhD candidate

Krystal Bergin:

Monash University, PhD completion 2022

Amanda Su:

University of Melbourne, Master of Epidemiology,
Research Project 2022

Daphne Antonopoulos:

University of Melbourne, Master of Cancer Sciences,
Research Project 2021

Rosalyn Cao:

Monash University, Master of Public Health,
Research Project 2019

Natthida Khajornjiraphan:

Monash University, Master of Clinical Research Methods,
Research Project 2019

Dervla O'Regan:

Monash University, Master of Clinical Pharmacy,
Research Project 2018

THANK YOU

The MRDR thanks participating individuals and sites, and our steering committee for all their work and contribution.

MRDR Steering Committee

Prof Andrew Spencer:

Alfred Hospital /
Monash University VIC

Dr Bradley Augustson:

Sir Charles Gairdner Hospital WA

Dr Krystal Bergin:

Alfred Hospital VIC

Prof Simon Harrison:

Peter Mac/Royal Melbourne VIC

Prof Joy Ho:

Royal Prince Alfred Hospital NSW

Dr Tracy King:

Royal Prince Alfred Hospital NSW

A/Prof Zoe McQuilten:

Monash University VIC

A/Prof Peter Mollee:

Princess Alexandra Hospital QLD

Prof Hang Quach:

St Vincent's Hospital,
Melbourne VIC

Dr Rajeev Rajagopal:

Middlemore Hospital NZ

Mr Brian Rosengarten:

Myeloma Australia

A/Prof Craig Wallington-Gates:

Flinders Medical Centre SA

Prof Erica Wood:

Monash University VIC

MRDR Management Committee

Coordinating Principal Investigator:

Prof Andrew Spencer

Head of Transfusion
Research Unit (TRU):

Prof Erica Wood

Associate Investigator:

A/Prof Zoe McQuilten

Research Fellow/ANZ MRDR

Project Manager:

Dr Elizabeth Moore

Data Manager:

Dr Cameron Wellard

ANZ MRDR Research Officer:

Dr Laura Sellick

Data Officer:

Dr Fiona Chen

TRU Deputy Director – Operations:

Mr Neil Waters

APAC MRDR Project Manager:

Ms Naomi Aoki

APAC MRDR Research Officer:

Ms Laura Oliver

Business Development Project
Manager (AMaRC):

Mr Khoa Le

Thank you to the following MRDR industry funding partners. We appreciate your support and look forward to a very productive 2023.

abbvie

AMGEN

ANTGENE

Bristol Myers Squibb™

Celgene

GILEAD

GSK

Janssen
PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

NOVARTIS

sanofi

Takeda



MONASH
University

CONTACT THE MYELOMA AND RELATED DISEASES REGISTRY (MRDR)

E: sphpm-myeloma@monash.edu

T: 1800 811326

W: mrdr.net.au

